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Abstract: Obesity in dogs is increasingly present in the veterinary practice. In humans, it is known that there is a significant correlation
between obesity and the development of hypertension and insulin resistance (IR), a clinical picture called metabolic syndrome. In dogs,
however, there are only anecdotes about the syndrome. The objectives of this study were to determine serum levels of adiponectin,
leptin, triglycerides, cholesterol, insulin, glucose, homeostasis assessment of B cell function (HOMA-B), homeostasis assessment of
insulin resistance (HOMA-IR), and systolic blood pressure (SBP) in dogs with different body conditions (BC) and body fat (BF) without
endocrine disease. For this purpose, 76 healthy dogs were submitted to evaluation of body conditions score (BCS) and morphometry.
The dogs were separated into 3 groups: optimal BC [BCS 3,4, or 5 of 9 and BF% of 13 to 27-Group 1 (G1)], overweight [BCS 6 and 7
of 9 and BF% of 14 to 38- Group 2 (G2)], obese [BCS 8 and 9 of 9 and BF% greater than or equal to 34-Group 3 (G3)]. G3 presented
higher serum levels of total protein, triglycerides, glucose, insulin, and HOMA-IR. Adipokines did not correlate to any other parameter,
but the occurrence of hyperinsulinemia was higher in G3. The results have shown that obese dogs presented IR and alterations in fat
metabolism.
Key words: Adipokines, systolic hypertension, obesity, insulin resistance

1. Introduction
Obesity is a disease that is increasingly present in veterinary
routine, representing more than 50% of attended dogs.
Certain risk factors have contributed to the increased
incidence in recent years, such as spaying, longevity, the
quality and quantity of food, and the lifestyle of the owners
[1].
Obesity reduces longevity and predisposes to the
development of several diseases such as musculoskeletal,
cardiorespiratory, and reproductive disorders [2].It is
known that adipose tissue acts on the supply of energy, the
protection of the organs, and is responsible for the synthesis
and secretion of various hormones and inflammatory
substances called adipokines [3].
In humans, the term “metabolic syndrome” (MS) is
used to explain a metabolic condition in which a person
has risk factors (among them the visceral obesity) that
predispose to cardiovascular disease and Type 2 diabetes
mellitus (T2DM) [4]. Moreover, hyperlipidemia and the
changes in the levels of adipokines caused by obesity
appear to be the keys to the development of IR and T2DM,

although the mechanisms involved are poorly understood
[5].
In dogs, the use of the term “MS” is controversial as
it has not been confirmed whether obese dogs are in
fact more likely to develop cardiovascular diseases and
metabolic diseases [6,7]. For this reason, Tvarijonaviciute
et al. [8] suggest the use of the term “obesity-related
metabolic dysfunction” (ORMD) and the characterization
of the syndrome based on different parameters and cutoff values. Among them is the need that the dog present
a body condition score higher than or equal to 7 (out of
9), associated with at least 2 of the following parameters:
triglycerides higher than 200mg/dL, total cholesterol higher
than 300mg/dL, systolic blood pressure (SBP) higher than
160mmHg, and fasting blood glucose higher than 100mg/
dL, or the confirmed diagnosis of diabetes mellitus.
It is believed that obese dogs have a predisposition to
develop clinical manifestations secondary to obesity; thus,
the present study aimed to investigate the occurrence of
changes in the metabolic and lipid profiles in overweight
dogs.
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This study aimed to define the metabolic and lipid
profiles and SBP in dogs with adequate BCSs, overweight or
obesity without endocrine diseases and thus to determine
the serum levels of glucose, insulin, triglycerides,
cholesterol, leptin, adiponectin, and SBP in 76 dogs with
different BCSs.
Also, this study aimed to evaluate the occurrence of
IR in overweight and obese dogs (by measurement of
blood glucose, serum insulin, and HOMA indexes) and
its association with the concentrations of adipokines and
insulin.
2. Material and Methods
2.1. Location and experimental groups
The samples for this multicenter study were obtained at
the College of Veterinary Medicine and Animal Science,
Paulista State University Júlio de Mesquita Filho, BotucatuSP, Brazil, at the State University of Northern Parana,
Bandeirantes-PR, Brazil, and at the State University of
Londrina, Londrina-PR, Brazil.
All the animals were healthy and were selected
randomly for the present study. The age of the animals
ranged from 2 to 16 years. The evaluated breeds were
diverse and consisted of Golden retrievers, Labradors,
poodles, Yorkshires, mixed breeds, malts, blue heelers,
Rottweilers, and Lhasa Apsos.
The animals in this study were separated into 3 groups:
optimal body condition [Group 1 (G1), n = 23], overweight
[Group (G2), n = 27], and obese [Group (G3), n = 26]. G1
was composed of dogs with BCS 3,4, or 5 of 9 and BF% of
13 to 27, G2 was composed of dogs with BCS 6 and 7 of 9
and BF% of 14 to 38, and G3 was composed of dogs with
BCS 8 and 9 of 9 and BF% greater than or equal to 34.
In relation to sex, there were 6 females spayedin G1,
6 in G2, and 11 in G3, and 7 uncastrated females in G1,7
in G2, and 5 in G3. Furthermore, there were 5 castrated
males inG1, 5 in G2 and G3, and 5 uncastrated males in
G1, 7 in G2, and 4 in G3.
2.2. Evaluation of body condition, morphometric measurements, and exclusion criteria
BCS was measured according to the 1–9 Body Condition
Score System (BCS) [9]. Morphometry [10] was evaluated
in addition to the BCS. Those animals in which the results
of morphometry and BCS were conflicting were excluded
from the experiment. Only 3 trained examiners did the
BCS assessment, strictly following the description of scale
1–9 proposed by Laflamme [9].
The exclusion criteria includedendocrine, liver, and
kidney diseases and those which were being treated
with glucocorticoid, anticonvulsants, and hypo or
hyperglycemic and hypotensive drugs. The diseases were
ruled out by clinical examination, hematologic evaluation,
urinalysis, and imaging.
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Hyperadrenocorticism was ruled out after
suppression test with low-dose dexamethasone [11] and
hypothyroidism after the thyroid function test.
2.3. Specimen collection and laboratory tests
The samples were collected after 12 h of fasting, in the
morning, by jugular venipuncture. The blood samples
were immediately stored in sterile tubes containing EDTA
and clot activator gel, being centrifuged within1 h after
collection. The blood serum samples were fractionated into
5 vials and frozen at −70°C in freezer until the moment of
testing.
The samples for glucose measurement were collected in
a flask containing sodium fluoride and sent for laboratory
analysis immediately after collection.
Complete blood count, urinalysis, glucose
measurement, and serum biochemistry exams were
processed at the Veterinary Clinical Laboratory of Paulista
State University Júlio de Mesquita Filho.
The serum concentrations of adiponectin and leptin
(Canine Adiponectin/Leptin ELISA, Millipore®, Billerica,
MA, USA) were measured using commercial kits of
enzyme-linked immunosorbent assay (ELISA) according
to the manufacturer’s recommendations. Interassay
sensitivity was 6.34% and 7.38% and intraassay sensitivity
was 4.19% and 5.41%, respectively, for adiponectin and
leptin.
The measurement of serum insulin was analyzed by
the IMMULITE 1000 analyzer using a commercial kit
(Millipore®, Billerica, MA, USA), with intraassay and
interassay sensitivity being 3.23% and 3.65%, respectively.
The samples were measured in duplicate.
The measurement of serum levels of total thyroxine,
free thyroxine, and cortisol were performed by
radioimmunoassay technique (WIZARD, 1470 Automatic
Gamma Counter, Perkin Elmer Inc., Waltham, MA,
USA) according to the recommendations of the kit’s
manufacturer (MP Biomedicals, California, CA, USA).
2.4. HOMA index calculation and noninvasive
measurement of systolic blood pressure (SBP)
The calculation of the homeostasis assessment (HOMA)
was performed as proposed by Matthews et al. [12] based
on the following equations: HOMA-IR = [Fasting insulin
level (µU/mL) × Fasting glucose level (mmol/L)] / 22.5;
and HOMA-%B= [20 × Fasting insulin level (µU/mL)] /
[fasting glucose level (mmol/L) − 3.5].
SBP was measured by the noninvasive method using a
Doppler flowmeter (Doppler Vascular DV 610, MedMega,
Distrito Industrial I, Franca ) as described by Henik et al.
[13].
The confirmation of hypertension was based on the
average SBP levels above 160mmHg following the ORMD
classification standards [8,14].
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2.5. Analysis of the results
The experimental design has considered the effects of BCS
on the variables of the percentage of body fat (%BF), SBP,
triglycerides, cholesterol, glucose, insulin, HOMA-IR,
HOMA-B, adiponectin, and leptin.
Although the groups differ in quantity, the number
of animals per group allowed statistical analyses to be
performed.
The variables did not show normality and
homoscedasticity by the Kolmogorov-Smirnov test and
Liliefors test (P < 0.05). Thus, the differences among dogs
grouped according to BCS (G1, G2, and G3) were analyzed
by the Kruskal-Wallis test with P < 0.05.
All the variables were related to each other through the
Spearman correlation and P < 0.05. All the analyses were
carried out in the Statistica 10.0 software.
3. Results
The results are presented in Figures 1, 2, and 3 as box
plots. The dogs classified as obese (G3) had higher levels of
triglycerides, blood glucose, insulin, and HOMA-IR.
The table shows the values obtained for leptin and
adiponectin in the different groups studied. It is noted
that there is no variation of adiponectin and leptin values
according to body condition. Besides that, adipokines
showed no significant correlation with any of the studied
variables.

4. Discussion
Melhman et al. [15] found that the SBP values were higher
in obese dogs, although they all were within the normal
range. This was also observed in this study, suggesting that
both the amount and the period of adiposity can influence
SBP values.It is possible that we did not detect a statistical
difference in the SBP values between G1, G2, and G3 due
to the fact that this was a study involving only animals with
spontaneous obesity. It is inferred that the rate of weight
gain and the type of diet can both influence the occurrence
of hypertension in dogs. Pérez-Sánches et al. [14], on the
other hand, do not consider obesity as a risk factor for
the development of hypertension, believing that there is
always an association with other diseases. In the current
study, however, other comorbidities were ruled out.
In this study, higher levels of triglycerides in
overweight and obese dogs are similar to those described
by others [5,16,17].It is inferred, therefore, that this may
be a risk factor for the development of hyperlipidemia.
The mechanisms involved are not clear, but it is believed
that genetic factors, fat distribution, diet imbalance, and
physical inactivity are associated.
In this study, higher levels of glucose, insulin, and
HOMA-IR in G3suggest that obese dogs do develop IR.
Similar findings of increased HOMA-IR in obese dogs
were described by Respondek et al. [18], demonstrating
the occurrence of IR.As observed in the present study,

Figure 1. Graphical representation of triglycerides, cholesterol and SBP in dogs with
different body conditions (G1, G2 and G3). Medians without letters or followed by equal
letters don’t differ in the Kruskal Wallis test (P < 0.05). G1: Group 1 (Optimal BC); G2:
Group 2 (Overweight); G3: Group 3 (Obese); Trig: triglycerides; SBP: systolic blood
pressure.
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Figure 2. Graphical representation of adiponectin and leptin values in dogs with different body
conditions (G1, G2 and G3). Medians without letters don’t differ in the Kruskal Wallis test (P <
0.05). G1: Group 1 (Optimal BC); G2: Group 2 (Overweight); G3: Group 3 (Obese).

Figure 3. Graphical representation of glucose, insulin, HOMA-IR e HOMA-B values in dogs
with different body conditions (G1, G2 and G3). Medians without letters or followed by equal
letters don’t differ in the Kruskal Wallis test (P < 0.05). G1: Group 1 (Optimal BC); G2: Group
2 (Overweight); G3: Group 3 (Obese); HOMA-IR: model for assessment of the homeostasis of
insulin resistance; HOMA-B: model for assessment of the homeostasis of B cell function.
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Table. Average, standard deviation and median of adiponectin
and leptin in G1, G2 and G3.

Leptin
(ng/dL)
Adiponectin
(µg/mL)

G1

G2

G3

Average

1.13

1.61

1.15

Standard D.

0.76

3.33

0.56

Medium

0.88

0.85

0.99

Average

6.87

5.53

6.99

Standard D.

2.76

2.62

2.90

Medium

6.84

4.98

6.91

Medians without letters did not differ in the Kruskal Wallis test
(P < 0.05).
G1: Group 1 (Optimal BC); G2: Group 2 (Overweight); G3:
Group 3 (Obese).

others have shown that obese dogs tend to have higher
concentrations of glucose[8,16,19-21].
It is noteworthy that most of the studies that found
no hyperglycemia in obese dogs worked with portable
glucometer and obesity induced by high-energy diets. It is
considered that the use of glucometer must be associated
with laboratory serum glucose analysis. Spontaneously
obese dogs manifest more changes in glucose levels than
experimentally-induced obese dogs, possibly because of
the adiposity time, the level of physical inactivity, and the
type of diet.
It is known that there is a variation in the measurement
of adipokines depending on the brand of the kits and
techniques. Also, itis believed that the storage time
of samples and tubes causes alterations and there are
differences in the sensitivity of tests for various existing
forms of adiponectin. In this study, specific and previously
reported commercial kits were used [5,19] and the samples
were stored for a shorter time than recommended by
the manufacturer. There were no differences in leptin
and adiponectin concentrations between groups and
adipokines were not correlated with any variables.
German et al. [22] used only dogs with owners and
the same kit used in this study for the evaluation of total
adiponectin serum levels. Similarly, in this study, Verkest
et al. [6] did not observe changes in adiponectin levels in
dogs due to overweight. These data suggest that dogs show
no variation in adiponectin concentrations.
In general, this study showed lower adiponectin values
in all groups than those found in the literature. Thus, dogs
with different body scores showed a serum adiponectin
concentration similar to those detected in obese cats [23].
Other authors, however, reported the occurrence of
either decreased adipokines levels in canine obesity or
increased levels in obese dogs after weight loss [5,8,16,19].

It is noticeable, however, that most of these studies were
conducted with experimentally induced obese dogs fed
high energy diets and the measurements were performed
using human kits.
In humans, it is believed that the development of
obesity-related disorders isdirectly associated with
decreases in the serum levels of adiponectin [8]. Previous
studies in cats have shown adiponectin behavior similar
to humans [23], although more recent studies have not
observed significant changes in adiponectin levels in obese
cats and after weight loss [24].In the studied population,
there were no changes in the levels of adipokines, and
probably this is a protective factor in the development of
MS and T2DM, as reported in other species.
This strengthens the hypothesis that obese dogs, despite
developing IR, are resistant to the development of DM
similar to type-2 in humans because of the compensatory
mechanisms that prevent changes in adiponectin and even
leptin levels, as occurred in the population studied here.
There are different isoforms of adiponectin from different
molecular weights [25,26]. Brunson et al. [27] detected a
similarity between the canine adiponectin molecule and
that of humans and rodents, and the expression of the
adiponectin gene was identified in the canine visceral
adipose tissue, which supports the hypothesis that
adipokines play an important role in canine metabolism.
Muñoz-Prieto et al. [28] showed the use of selective
protease digestion to detect canine serum as a procedure
to detect different isomers of adiponectin. This technique
was not used in the present study, and therefore, some
isoforms may not have been detected.
It is emphasized that metabolic studies are necessary to
investigate the differences in dog metabolism.
Several researchers have found the occurrence of
hyperleptinemia in obese dogs [5,16,17]. As mentioned
before, these findings must be carefully interpreted because
there is a range of kits and methodologies used, as well
as the storage time and the type of sample used (serum
or plasma). In addition, the studies are not identical, as
there seems to be a difference between subcutaneous and
visceral adipose tissue on adipokine levels[29],which was
not evaluated in these studies.In the present study, there
were no changes in leptin levels. German et al. [22] found
values below the detection threshold using the same kits
of this study. As observed here, Müller et al. [30] found no
correlation between adiposity or leptin concentrations and
insulin levels or IR.
The constancy in the levels of adipokines observed in
different groups can be justified by the fact that this was
a clinical study, all the included animals had owners, and
none had experimentally-induced obesity, which means
that it is not possible to determine the diet and to estimate
how long each individual dog was overweight or obese.
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Recent studies have shown that different diets can
influence the levels of circulating adiponectin and leptin
[31], which can also justify differences between the levels
of adipokines detected in different studies cited, since this
parameter has not been evaluated.
Therefore, a key to detect the changes in the levels
of adipokines and even the development of metabolic
disorders in dogs with increased BF may be the
determination of the diet and the duration of overweight
or obesity, as well as performing longitudinal studies.
Furthermore, it is important to emphasize the distinction
between quickly induced obesity and those cases in which
the dog’s weightslowly increases over the years, since the
resulting disorders may be different.
In humans, low levels of adiponectin are related to
disorders such as atherosclerosis, T2DM, and insulin
resistance [26]. Dogs seem to keep higher adiponectin
levels than humans, which may act as a protective
factor in dogs, preventing the development of T2DM.
When comparing the levels of adiponectin with cats, there
also seem to be differences, since in cats, which develop
DM similar to T2 in humans, there are differences between
the levels of adiponectin according to body condition[23].
However, recent studies have not confirmed that this is
significant [24].

5. Conclusion
The results obtained allowed concluding that obese
dogs have higher levels of triglycerides, glucose, insulin,
HOMA-IR, and higher SBP when compared to dogs with
optimal BC and overweight.
However, adipokines do not seem to correlate with any
of the other studied variables and do not vary according to
BC. This constancy in the level of adipokines probably is
a protective factor in the development of MS and T2DM
in dogs.
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